ONKT-102

N/A

Report date: 2025/05/08 16:35:29

Base Information

Drug NameONKT-102
Drug Alias NameONKT-102
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapy
Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacementsLymphocyte differentiation antigen CD38 inhibitors
TargetsLymphocyte differentiation antigen CD38
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIreland
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesVu University Medical CenterONK Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesONK Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A